• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】53010

【品名】2-[(7R,8R,9S,13R,14S,17R)-7,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl acetate

【CA登记号】n/a

【 分 子 式 】C23H34O3

【 分 子 量 】358.52116

【元素组成】C 77.05% H 9.56% O 13.39%

与该中间体有关的原料药合成路线共 1 条

合成路线1

该中间体在本合成路线中的序号:(XIV)

A different strategy for preparing the target 6-methylated steroid nucleus was based on the conjugate addition of an organocuprate reagent to a dienone. The intermediate hydroxy enone (IV) was acylated with isopropenyl acetate to produce the bis-acetate (XII). Bromination of (XII) with N-bromosuccinimide, followed by dehydrohalogenation with Li2CO3 and LiBr in refluxing DMF, gave rise to dienone (XIII). Conjugate addition of methyllithium to (XIII) in the presence of CuI afforded the methylated compound (XIV). Aromatization of the cyclohexenone system was achieved by oxidation with CuCl2. Subsequent acetate ester hydrolysis under basic conditions generated diol (XV), which was converted to the bis-mesylate (XVI) upon treatment with methanesulfonyl chloride and Et3N. Displacement of the aliphatic mesylate with vanillic acid diethylamide (VII) yielded ether (XVII). Then, simultaneous amide reduction and reductive cleavage of the aryl mesylate with LiAlH4 provided the title compound.

1 Peters, R.H.; Tanabe, M.; Chao, W.-R.; Johansson, J.G.; Ryan, K.J.; Liu, J. (SRI International); Synthesis of anti-estrogenic acid and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one. WO 0158919 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(IV) 53001 (8R,9S,13R,14S,17R)-17-(2-hydroxyethyl)-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one n/a C20H30O2 详情 详情
(VII) 53004 N,N-diethyl-4-hydroxy-3-methoxybenzamide n/a C12H17NO3 详情 详情
(XII) 53003 (7S,8S,9S,13R,14S,17R)-17-(2-hydroxyethyl)-3-isopropoxy-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one n/a C24H34O3 详情 详情
(XIII) 53009 2-[(8S,9S,13R,14S,17R)-13-methyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl acetate n/a C22H30O3 详情 详情
(XIV) 53010 2-[(7R,8R,9S,13R,14S,17R)-7,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl acetate n/a C23H34O3 详情 详情
(XV) 53011 (7R,8S,9S,13R,14S,17R)-17-(2-hydroxyethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol n/a C21H30O2 详情 详情
(XVI) 53012 (7R,8S,9S,13R,14S,17R)-7,13-dimethyl-17-{2-[(methylsulfonyl)oxy]ethyl}-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl methanesulfonate n/a C23H34O6S2 详情 详情
(XVII) 53013 (7R,8S,9S,13R,14S,17R)-17-(2-{4-[(diethylamino)carbonyl]-2-methoxyphenoxy}ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl methanesulfonate n/a C34H47NO6S 详情 详情
Extended Information